Last month, saw the launch of ICER Analytics, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices, and explore new ways to apply evidence in a drive toward a health system that can achieve fair prices and fair access for all. While all of ICER’s reports will remain in the public domain as downloadable PDFs from our website, ICER Analytics comprises two tools geared toward frequent users of ICER’s work: the ICER Evidence Compendium™, a rapidly searchable and sortable summary of results from ICER’s library of evidence reports; and the ICER Interactive Modeler™, which enables stakeholders to customize our economic models based on their own assumptions and cost structures.
ICER is working with the National Health Council to enable many patient organizations to access ICER Analytics for free. In addition, they’re providing free access to all HTA organizations from low- or middle-income countries. For all other stakeholders, subscription prices will be scaled by organization type and size. Any potential users interested in learning more are encouraged to complete this survey. And if you missed yesterday’s webinar, where representatives from both the payer and pharmaceutical industries demoed the tool and discussed how they plan to turn ICER insights into policy action, you can watch the recording here. Find out more about ICER Analytics™ here.
